Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EPO906
epothilone b · 8 trials · 12 indications
Objective tumor response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines assessed by radiologic techniques and/or physical examination.
tumor response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST).
| Arm | Type | Description |
|---|---|---|
| Patupilone | EXPERIMENTAL | - |
| doxorubicin | ACTIVE_COMPARATOR | - |
| EPO906 | EXPERIMENTAL | - |
| Bolus | EXPERIMENTAL | 20 min bolus infusion |
| CIV-1d | EXPERIMENTAL | 1 day continuous infusion |
| CIV-5d | EXPERIMENTAL | 5 day continuous infusion |
| Name | Type | Description |
|---|---|---|
| EPO906 (Patupilone) | DRUG | - |
| doxorubicin | DRUG | - |
| epothilone b | DRUG | - |
Inclusion Criteria: * 18 years of age or older * Confirmed diagnosis of ovarian, fallopian or peritoneal cancer * No more than three chemotherapy regimens * Most recent regimen must have been platinum based Exclusion Criteria: * Have an unresolved bowel obstruction * Have had previous chemotherap...
Epothilone B is an investigational small molecule being studied in oncology for several solid tumor types, including breast, colorectal, kidney, ovarian and prostate cancers and melanoma. It is in Phase 2 clinical development and has not been approved for any indication.
Epothilone B targets tubulin, binding beta-tubulin subunits including TUBB4B, TUBB1 and TUBB3 and alpha-tubulin subunits such as TUBA1A, TUBA3C and TUBA4A. It acts as a tubulin stabiliser, promoting microtubule assembly and interfering with cell division in tumor cells.
Epothilone B is being developed by Novartis AG, which trades under the ticker NVS. The compound, also known as EPO906, has been studied in Novartis-sponsored Phase 2 oncology trials.
Epothilone B is in Phase 2 clinical development. It is investigational and has not received FDA approval. Its clinical program includes completed Phase 2 studies in kidney cancer, melanoma, breast cancer and prostate cancer.
Epothilone B has been evaluated in completed Phase 2 trials including NCT00035243 in advanced kidney cancer, NCT00035165 in advanced melanoma, NCT00035126 in advanced breast cancer and NCT00035113 in prostate cancer. These studies enrolled adults and were conducted in the United States and France.
Yes, EPO906 is an alternative name for epothilone B. Both names refer to the same investigational Novartis compound, a small molecule tubulin stabiliser studied in Phase 2 oncology trials.